Events (Public)

Myles Wolf, MD, MMSc, Myles Wolf, M.D., MMSc, Charles Johnson, M.D. Distinguished
Professor of Medicine Chief, Division, of Nephrology, Department of Medicine
Duke University School of Medicine will present “FGF23 at the Intersection of Kidney and Cardiovascular Disease.”

OBJECTIVES:

• Discuss the role of FGF23 in normal mineral
  metabolism and in chronic kidney disease.
• Identify the off-target cardiovascular effects of
  FGF23.
• Evaluate mechanisms of FGF23 regulation.

COMPETENCIES: Patient Care, Medical Knowledge

AUDIENCE: Internists, family practitioners, fellows, residents, medical students, allied health professionals and community physicians.

ACCREDITATION
Eastern Virginia Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Eastern Virginia Medical School designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE
Myles Wolf, M.D., MMSc serves a consultant for Pharmacosmos, Launch, and Enyo. He is a member of the Scientific Advisory Board for Walden and Unicycive. He is on the Board of Directors for Akebia Therapeutics, Inc. All financial relationships have been mitigated. The planning
committee members have no relevant financial relationships with ineligible companies to disclose.